Alnylam Pharmaceuticals
Developing RNAi therapeutics
- B2B
- Has physical offices
- Publicly traded
- Manufacturing
- Healthtech
- Sales-led purchase
About Alnylam Pharmaceuticals
A global biotech company pioneering RNAi therapeutics to treat rare genetic diseases, with a breakthrough product and a robust pipeline
Key facts
- Industry
- Biotechnology Research
- Company size
- 1,001–5,000 employees
- Headquarters
- cambridge, massachusetts, United States
- Founded
- 2002
- Revenue
- €86.1MFY2025, filed accounts, INPI
- Website
- alnylam.com
Jobs at Alnylam Pharmaceuticals
Alnylam Pharmaceuticals in the news
- Alnylam invests $250m to boost RNAi manufacturing in the US
Alnylam is investing $250 million to expand its Massachusetts facility with an FDA-accepted enzymatic ligation platform to boost RNAi therapeutic manufacturing capacity and reduce costs.
- Here’s Why Alnylam Pharmaceuticals (ALNY) Surged in Q3
Alnylam Pharmaceuticals saw a strong stock surge and 103% revenue growth in Q3 2025, driven by a successful Amvuttra launch.
- Alnylam Pharmaceuticals (ALNY) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025
Alnylam Pharmaceuticals is transitioning to a commercial-scale biotech with strong revenue growth from Amvuttra, Nasdaq-100 inclusion, UK reimbursement approval, manufacturing expansion, and ongoing federal scrutiny.
- Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by U.S. Capital Wealth Advisors LLC
Alnylam Pharmaceuticals saw notable insider and institutional stock sales amid generally positive analyst ratings, continuing its focus on RNAi therapeutics development.
- Demand prompts Alnylam’s $250 million manufacturing expansion
Alnylam is investing $250 million to expand its Massachusetts facility to boost siRNA therapeutic manufacturing capacity and reduce costs.
Alnylam Pharmaceuticals at a glance
Alnylam Pharmaceuticals is a B2B company in the Biotechnology Research industry, headquartered in cambridge, massachusetts, United States.
Alnylam Pharmaceuticals was founded in 2002.
Alnylam Pharmaceuticals has 1,001–5,000 employees.
Alnylam Pharmaceuticals's revenue is €86.1M (FY2025, filed accounts, INPI).
Alnylam Pharmaceuticals is hiring: 1 recent open role, including Associate Director, Clinical Quality and Continuous Improvement.
Selling to companies like Alnylam Pharmaceuticals?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies